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Background: Dipeptidyl peptidase IV (DPP-IV) is not only important in pancreatic `-cell regulation but also has proinflammatory actions that 
can contribute to atherosclerosis progression. Previously we showed that DPP-IV may also lead to atherosclerotic plaque vulnerability in part by 
promoting neoangiogenesis within the plaque. These characteristics of DPP-IV may predispose patients with coronary artery disease (CAD) to plaque 
rupture and thus to myocardial infarction. The goal of this investigation was to determine whether genetic alterations in DPP-IV predispose to plaque 
vulnerability and myocardial infarction (MI).
Methods: Between Aug 1, 2004, and March 31, 2007, blood samples of patients with angiographically documented CAD were banked at 
Washington Hospital Center. Demographic, clinical, risk factor, and angiographic data were recorded. 875 patients of European ancestry with 
angiographic CAD were divided into those with MI (n=421) and those without (n=454). A genome-wide association study was performed using the 
Affymetrix 6.0 chip to identify loci that predispose to MI. In the current study we assessed the association of single nucleotide polymorphisms (SNPs) 
in the DPP-IV gene region and risk of MI in patients with CAD. For genotyped SNPs, association was tested by logistic regression with the assumption 
of additive genetic effects and the significance level of 0.05.
Results: Average patients’ age at diagnosis of CAD was 46.8 years for MI group and, by design, was higher (50.8) in the non MI group. We tested 
the association of DPP-IV SNPs with risk of MI in patients with CAD. From 25 SNPs in the DPP-IV and promoter region, we identified 6 SNPs that 
were significantly related to angiographic CAD with MI, but not to angiographic CAD without MI (odds ratio: 1.22-1.34, p<0.05). The association of 
Identified SNPs to the risk of MI was not attenuated after adjustment for traditional risk factors.
Conclusions: Polymorphisms in dipeptidyl peptidase IV gene, in patients with known CAD, may increase the risk of MI.
